Navigation Links
Clinical Safety Data for ChromaDex®'s Patented pTeroPure® (pterostilbene) Released at 6th World Congress on Polyphenols Applications in Paris
Date:6/13/2012

IRVINE, Calif., June 13, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries announced today its patented pTeroPure (pterostilbene) was shown to be safe for human consumption according to data from the first clinical trial of the substance. The findings, based on a study with pTeroPure, were presented at the 6th World Congress on Polyphenols Applications in Paris, France on June 7, 2012.(1) Pterostilbene is an antioxidant found in blueberries and other berries and believed by many experts to have a number of health benefits. pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

"The safety of pterostilbene has previously been demonstrated in numerous cell and animal studies and we are pleased to find it translates to humans as well," said the study's principle investigator Daniel Riche, PharmD, Cardiometabolic Clinic Coordinator at the University of Mississippi School of Pharmacy. "These results further support pTeroPure's self-affirmed GRAS status and should leave no doubt that it is safe for human use in consumer products."

The study, a double-blind, randomized, placebo-controlled trial, included 80 adults who were given 100 to 250 mg per day of pTeroPure or placebo for 6-8 weeks. The results showed a lack of adverse reactions and no major adverse events. Data analyses from the trial on the effects of pTeroPure on blood pressure, triglycerides, cholesterol and oxidative stress are currently underway, and results are expected to be made public following acceptance in a peer-reviewed journal. The study was a collaboration between the University of Mississippi and ChromaDex.

Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other antioxidant polyphenols (substances from plants that tend to prevent or neutralize the damaging effects of free radicals), resulting in more prolonged antioxidant activity. Along with a number of other effects, pterostilbene has shown great promise for supporting heart health, cognitive function and anti-aging.

"ChromaDex is committed to investing in human studies to provide the clinical evidence for our novel ingredients that the industry expects," said Frank Jaksch Jr., CEO and co-founder of ChromaDex. "These safety results fulfill an important prerequisite to expanding pTeroPure into our various business channels in the United States and abroad. We also are optimistic about the efficacy data, scheduled to be released within a few months. This is only one of our many planned studies intended to contribute to our mission of bringing solutions to our customers to help promote health and wellness."

pTeroPure is the key novel ingredient in BluScience™, ChromaDex's recently launched line of dietary supplements. BluScience, which is now available at a major drug store chain, GNC and an online retailer, Drugstore.com, is expected to be available in more than 25,000 retail stores by year-end 2012, as well as through major online retailers.

About ChromaDex®:
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights. The company recently launched its BluScience™ line of dietary supplements, now available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S. through a distribution agreement with one of the largest pharmaceutical distributors in North America. BluScience is also available at a prominent online retailer, as well as a national health and nutrition products retailer. Capitalizing on the diverse potential applications of the product, ChromaDex is also investigating pTeroPure for the skincare and pharmaceutical markets, among others. For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

(1) McEwen CL. Analysis of safety from a human clinical trial with pterostilbene. Poster presentation at: International Society of Antioxidants in Nutrition and Health (ISANH) 6th World Congress on Polyphenols Applications: Paris Polyphenols 2012. June 7-8, 2012, Paris France.

ChromaDex Investor Contact:                                             

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

or

Alex Partners, LLC
Scott Wilfong, President
425-242-0891
Scott@alexpartnersllc.com

ChromaDex Contact:

Laura Carney, Executive Assistant
949-419-0288
laurac@chromadex.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
2. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
3. Pycnogenol® (French Maritime Pine Bark Extract) Shown To Improve Endothelial Function And Reduce Oxidative Stress In New Clinical Trial
4. Global BioClinical Welcomes Jennifer Maas as Senior Consultant
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System
8. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
9. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
10. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
11. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...
(Date:12/8/2016)... -- A new study by a pair of Geisinger Health ... to treat chronic pain is not only ineffective, it ... including death. Palliative care physicians Mellar ... M.D., authored the study which provides a review of ... was published in the December 2016 edition of Current ...
(Date:12/8/2016)... 2016  EIP Pharma, LLC ( www.eippharma.com ) ... neflamapimod (previously code named VX-745), with the results ... that demonstrated significant Alzheimer,s disease relevant pharmacological activity.  ... Study 303 (6-week treatment) are the subject of ... (CTAD) scientific conference in San Diego, ...
Breaking Medicine Technology:
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 , ... ... decreases in medical payments per workers’ compensation claim in 2013 and 2014, according to ... Workers Compensation Research Institute (WCRI) . , According to the study, medical payments per ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael Insurance Agency, ... Hamilton County, is embarking on a charity drive with the aim of generating ... for orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a locally owned ... clients in the northern Alabama and Georgia regions, is embarking on a charity ... Works has built a network of support and education facilities to develop and ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kenall Manufacturing, ... new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that ... amount of light where and when it’s needed. , A 2’ x ...
(Date:12/7/2016)... Atlanta, Georgia (PRWEB) , ... ... ... announced today it has acquired Presence Technology, S.L. (“Presence”) for a purchase ... certain price adjustments and other considerations. Presence’s annual revenue is approximately $13.2 ...
Breaking Medicine News(10 mins):